Skip to main content
SpringerLink
Log in

Gastroesophageal Reflux in Children

Pathogenesis, Prevalence, Diagnosis, and Role of Proton Pump Inhibitors in Treatment

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

A substantial percentage of infants, children and adolescents experience gastroesophageal reflux disease (GERD) and its accompanying symptoms, as well as disease complications. The diagnosis of GERD in children is made based upon the child’s history, and data derived primarily from pH monitoring tests and endoscopy. In those children with confirmed reflux disease, the options for management parallel those recommended in adult patients, with the first step consisting of lifestyle changes. Surgical procedures may also be performed; however, these are rarely recommended prior to an adequate course of pharmacologic therapy, and appropriate case selection is important.

Among the current pharmacotherapeutic options available in the US, the prokinetic agents and the acid-inhibitory agents (histamine-2 receptor antagonists, proton pump inhibitors) are the most widely used. The clinical utility of the prokinetic agents has been limited by the recent withdrawal of cisapride from the US marketplace and the potential for irreversible central nervous system complications with metoclopramide. Numerous clinical studies performed in adults, and several studies involving children, have demonstrated that the proton pump inhibitors are more effective than the histamine-2 receptor antagonists in the relief of GERD symptoms and healing of erosive esophagitis. In children, omeprazole and lansoprazole may be administered as the intact oral capsule, or in those who are unable or unwilling to swallow, the granule contents of the capsule may be mixed with soft foods (e.g. apple sauce) or fruit drinks/liquid dietary supplements prior to oral administration with no detrimental effects on pharmacokinetics, bioavailability, or pharmacodynamics. Studies performed with omeprazole and lansoprazole in children have shown pharmacokinetic parameters that closely resemble those observed in adults. In over a decade of use in adults, the proton pump inhibitor class of agents has been found to have a good safety profile. Studies involving children have also shown these agents to be well tolerated. In numerous drug-drug interaction studies performed with these two proton pump inhibitors, relatively few clinically significant interactions have been observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal oesophagus: a quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62: 325–30

    PubMed  CAS  Google Scholar 

  2. Johnsson F, Joelsson B, Isberg P-E. Ambulatory 24 hour intraesophageal pH-monitoring in the diagnosis of gastroesophageal reflux disease. Gut 1987; 28: 1145–50

    Article  PubMed  CAS  Google Scholar 

  3. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–56

    Article  PubMed  Google Scholar 

  4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122(5): 1500–11

    Article  PubMed  Google Scholar 

  5. Heartburn across America: a Gallup Organization national survey. Princeton (NJ): Gallup Organization, 1988

  6. Nelson SP, Chen EH, Syniar GM, et al., for the Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med 2000; 154: 150–4

    PubMed  CAS  Google Scholar 

  7. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569–72

    Article  PubMed  CAS  Google Scholar 

  8. Gibbons TE, Stockwell JA, Kreh RP, et al. The status of gastroesophageal reflux disease in hospitalized US children 1995–2000 [abstract]. J Pediatr Gastroenterol Nutr 2001; 33(4): 197

    Google Scholar 

  9. Dahl M, Thommessen M, Rasmussen M, et al. Feeding and nutritional characteristics in children with moderate or severe cerebral palsy. Acta Paediatr 1996; 6: 697–701

    Article  Google Scholar 

  10. Reilly S, Skuse D, Poblete X. Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. J Pediatr 1996; 6: 877–82

    Google Scholar 

  11. Gisel EG, Birnbaum R, Schwartz S. Feeding impairments in children: diagnosis and effective intervention. Int J Orofacial Myology 1998; 24: 27–33

    PubMed  CAS  Google Scholar 

  12. Schwarz SM, Corredor J, Fisher-Medina J, et al. Diagnosis and treatment of feeding disorders in children with developmental disabilities. Pediatrics 2001; 108: 671–6

    Article  PubMed  CAS  Google Scholar 

  13. Andze G, Brandt M, St-Vil D, et al. Diagnosis and treatment of gastroesophageal reflux in 500 children with respiratory symptoms: value of pH monitoring. J Pediatr Surg 1991; 26: 295–9

    Article  PubMed  CAS  Google Scholar 

  14. Tucci F, Resti M, Fontana R, et al. Gastroesophageal reflux and bronchial asthma: prevalence and effect of cisapride therapy. J Pediatr Gastroenterol Nutr 1993; 17: 265–70

    Article  PubMed  CAS  Google Scholar 

  15. Martin ME, Grunstein MM, Larsen GL. The relationship of gastroesophageal reflux to nocturnal wheezing in children with asthma. Ann Allergy 1982; 49: 318–22

    PubMed  CAS  Google Scholar 

  16. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32Suppl. 2: S1–31

    Article  PubMed  Google Scholar 

  17. Gustafsson PM, Kjellman NI, Tibbling L. A trial of ranitidine in asthmatic children and adolescents with or without pathological gastro-oesophageal reflux. Eur Respir J 1992; 5: 201–6

    PubMed  CAS  Google Scholar 

  18. Balson BM, Kravitz EKS, McGeady SJ. Diagnosis and treatment of gastroesophageal reflux in children and adolescents with severe asthma. Ann Allergy Asthma Immunol 1998; 81: 159–64

    Article  PubMed  CAS  Google Scholar 

  19. Callahan CW. The diagnosis of gastroesophageal reflux in hospitalized infants: 1971–1995. J Am Osteopath Assoc 1998; 98: 32–4

    PubMed  CAS  Google Scholar 

  20. Ashorn M, Ruuska T, Karikoski R, et al. The natural course of gastroesophageal reflux disease in children. Scand J Gastroenterol 2002; 37: 638–41

    Article  PubMed  CAS  Google Scholar 

  21. Carr MM, Nguyen A, Nagy M, et al. Clinical presentation as a guide to the identification of GERD in children. Int J Pediatr Otorhinolaryngol 2000; 54: 27–32

    Article  PubMed  CAS  Google Scholar 

  22. Ramesh P, Braden D, Dey S, et al. Prevalence of gastroesophageal reflux disease (GERD) symptoms in a Caucasian predominant adolescent population [abstract]. Gastroenterology 2002; 122(4): A–213

    Google Scholar 

  23. Ramesh P, Santiago M, Schmidt K, et al. Prevalence of gastroesophageal reflux disease symptoms in an African American predominant adolescent high school population [abstract]. J Pediatr Gastroenterol Nutr 2001; 33: A194

    Google Scholar 

  24. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51Suppl. 1: 24–9

    Article  PubMed  Google Scholar 

  25. Treem WR, Davis PM, Hyams JS. Gastroesophageal reflux in the older child: presentation, response to treatment and long-term follow-up. Clin Pediatr (Phil) 1991; 30: 435–40

    Article  CAS  Google Scholar 

  26. Kane RE, Sarr M, Foy TM. Omeprazole versus lansoprazole in the treatment of children with peptic esophagitis refractory to H2 antagonists [abstract]. Gastroenterology 1997; 112Suppl. 4: A166

    Google Scholar 

  27. Bohmer CJ, Niezen-de Boer MC, Klinkenberg-Knol EC, et al. The prevalence of gastroesophageal reflux in institutionalized intellectually disabled individuals. Am J Gastroenterol 1999; 94: 804–10

    PubMed  CAS  Google Scholar 

  28. Rogers B, Stratton P, Msall M, et al. Long-term morbidity and management strategies of tracheal aspiration in adults with severe developmental disabilities. Am J Ment Retard 1994; 98: 490–8

    PubMed  CAS  Google Scholar 

  29. Werlin SL, Dodds WJ, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in children. J Pediatr 1980; 97: 244–9

    Article  PubMed  CAS  Google Scholar 

  30. Orenstein SR. Gastroesophageal reflux. Curr Probl Pediatr 1991; 21(5): 193–241

    Article  PubMed  CAS  Google Scholar 

  31. Lagergren J, Bergstrom R, Lindgrena A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–31

    Article  PubMed  CAS  Google Scholar 

  32. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998; 158: 2373–6

    Article  PubMed  CAS  Google Scholar 

  33. Euler AR, Ament ME. Value of esophageal manometric studies in the gastroesophageal reflux of infancy. Pediatrics 1977; 59: 58–61

    PubMed  CAS  Google Scholar 

  34. Herbst JJ, Book LS, Bray PF. Gastroesophageal reflux in the “near miss” sudden infant death syndrome. J Pediatr 1978; 92: 73–5

    Article  PubMed  CAS  Google Scholar 

  35. Ze Hu F, Preston R, Post J, et al. Mapping of a gene of severe pediatric gastroesophageal reflux to chromosome 13q14. JAMA 2000; 284: 325–34

    Article  Google Scholar 

  36. Vandenplas Y. The diagnosis and treatment of gastroesophageal reflux disease in infants and children. Ann Med 1993; 25: 323–8

    Article  PubMed  CAS  Google Scholar 

  37. Faubion W, Zein N. Gastroesophageal reflux in infants and children. Mayo Clin Proc 1998; 73: 166–73

    Article  PubMed  Google Scholar 

  38. Szarka LA, DeVault KR, Murray JA. Diagnosing gastroesophageal reflux disease. Mayo Clin Proc 2001; 76: 97–101

    Article  PubMed  CAS  Google Scholar 

  39. Gilger MA, Dietrich C, Gold B, et al. Does the endoscopic impression accurately predict histology in pediatric EGD [abstract]. Gastroenterology 2002; 122: A80

    Google Scholar 

  40. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease: current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303–14

    PubMed  CAS  Google Scholar 

  41. Yaseen M, Casteel HB. Gastroesophageal reflux in children. J Ark Med Soc 1996; 92(8): 390–6

    PubMed  CAS  Google Scholar 

  42. Saxena V, Fienes L, Bland JM, et al. A short course of lansoprazole provides an accurate diagnostic test for symptomatic GORD [abstract]. Gut 1999; 44Suppl. 2: A113

    Google Scholar 

  43. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Gastric polyps during longterm omeprazole treatment for gastroesophageal reflux disease [abstract]. Gastroenterology 1997; 112: A281

    Google Scholar 

  44. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 42–9

    Article  PubMed  CAS  Google Scholar 

  45. Iacono G, Carroccio A, Cavataio F, et al. Gastroesophageal reflux and cow’s milk allergy in infants: a prospective study. J Allergy Clin Immunol 1996; 97: 822–7

    Article  PubMed  CAS  Google Scholar 

  46. Hill DJ, Cameron DJ, Francis DE, et al. Challenge confirmation of late-onset reactions to extensively hydrolyzed formulas in infants with multiple food protein intolerance. J Allergy Clin Immunol 1995; 96: 386–94

    Article  PubMed  CAS  Google Scholar 

  47. Cavataio F, Iacono G, Montalto G, et al. Gastroesophageal reflux associated with cow’s milk allergy in infants: which diagnostic examinations are useful. Am J Gastroenterol 1996; 91: 1215–20

    PubMed  CAS  Google Scholar 

  48. Cavataio F, Iacono G, Montalto G, et al. Clinical and pH-metric characteristics of gastro-oesophageal reflux secondary to cows’ milk protein allergy. Arch Dis Child 1996; 75: 51–6

    Article  PubMed  CAS  Google Scholar 

  49. Vandenplas Y, Sacre L. Milk-thickening agents as a treatment for gastroesophageal reflux. Clin Pediatr 1987; 26: 66–8

    Article  CAS  Google Scholar 

  50. Bailey DJ, Andres JM, Danek GD, et al. Lack of efficacy of thickened feeding as treatment for gastroesophageal reflux. J Pediatr 1987; 110: 187–9

    Article  PubMed  CAS  Google Scholar 

  51. Orenstein SR, Magill HL, Brooks P. Thickening of infant feedings for therapy of gastroesophageal reflux. J Pediatr 1987; 110: 181–6

    Article  PubMed  CAS  Google Scholar 

  52. Meyers WF, Herbst JJ. Effectiveness of positioning therapy for gastroesophageal reflux. Pediatrics 1982; 69: 768–72

    PubMed  CAS  Google Scholar 

  53. Vandenplas Y, Scre-Smits L. Seventeen-hour continuous esophageal pH monitoring in the newborn: evaluation of the influence of position in asymptomatic and symptomatic babies. J Pediatr Gastroenterol Nutr 1985; 4: 356–61

    Article  PubMed  CAS  Google Scholar 

  54. Tobin JM, McCloud P, Cameron DJ. Posture and gastroesophageal reflux: a case for left lateral positioning. Arch Dis Child 1997; 76: 254–8

    Article  PubMed  CAS  Google Scholar 

  55. Oyen N, Markestad T, Skaerven R, et al. Combined effects of sleeping position and prenatal risk factors in sudden infant death syndrome: the Nordic Epidemiological SIDS Study. Pediatrics 1997; 100: 613–21

    Article  PubMed  CAS  Google Scholar 

  56. American Academy of Pediatrics. Task Force on Infant Sleep Position and Sudden Infant Death Syndrome. Changing concepts of sudden infant death syndrome: implications for infant sleeping environment and sleep position. Pediatrics 2000; 105: 650–6

    Article  Google Scholar 

  57. Mattioli G, Repetto P, Carlini C, et al. Laparoscopic vs open approach for the treatment of gastroesophageal reflux in children. Surg Endosc 2002; 16: 750–2

    Article  PubMed  CAS  Google Scholar 

  58. Tovar JA, Olivares P, Diaz M, et al. Functional results of laparoscopic fundoplication in children. J Pediatr Gastroenterol Nutr 1998; 26: 429–31

    Article  PubMed  CAS  Google Scholar 

  59. Veit F, Schwagten K, Auldist AW, et al. Trends in the use of fundoplication in children with gastro-oesophageal reflux. J Paediatr Child Health 1995; 31: 121–6

    Article  PubMed  CAS  Google Scholar 

  60. Randolph J. Experience with the Nissen fundoplication for correction of gastroesophageal reflux in infants. Ann Surg 1983; 198: 579–84

    Article  PubMed  CAS  Google Scholar 

  61. Bensoussan AL, Yazbeck S, Carceller-Blanchard A. Results and complications of Toupet partial posterior wrap: 10 years’ experience. J Pediatr Surg 1994; 29: 1215–7

    Article  PubMed  CAS  Google Scholar 

  62. Ahrens P, Heller K, Beyer P, et al. Antireflux surgery in children suffering from reflux-associated respiratory diseases. Pediatr Pulmonol 1999; 28: 89–93

    Article  PubMed  CAS  Google Scholar 

  63. Bergmeijer JH, Harbers JS, Molenaar JC. Function of pediatric Nissen-Rossetti fundoplication followed up into adolescence and adulthood. J Am Coll Surg 1997; 184: 259–61

    PubMed  CAS  Google Scholar 

  64. Dunn JC, Lai EC, Webber MM, et al. Long-term quantitative results following fundoplication and antroplasty for gastroesophageal reflux and delayed gastric emptying in children. Am J Surg 1998; 175: 27–9

    Article  PubMed  CAS  Google Scholar 

  65. Caniano DA, Ginn-Pease ME, King DR. The failed antireflux procedure: analysis of risk factors and morbidity. J Pediatr Surg 1990; 25: 1022–6

    Article  PubMed  CAS  Google Scholar 

  66. Rothenberg SS. Experience with 220 consecutive laparoscopic Nissen fundoplication in infants and children. J Pediatr Surg 1998; 33: 274–8

    Article  PubMed  CAS  Google Scholar 

  67. Dalla Vecchia LK, Grosfeld JL, West KW, et al. Reoperation after Nissen fundoplication in children with gastroesophageal reflux: experience with 130 patients. Ann Surg 1997; 226: 315–21

    Article  PubMed  Google Scholar 

  68. Fonkalsrud EW, Ashcraft KW, Coran AG, et al. Surgical treatment of gastroesophageal reflux in children: a combined hospital study of 7467 patients. Pediatrics 1998; 101: 419–22

    Article  PubMed  CAS  Google Scholar 

  69. Hassall E. Wrap session: is the Nissen slipping? Can medical treatment replace surgery for severe gastroesophageal reflux disease in children. Am J Gastroenterol 1995; 90: 1212–20

    PubMed  CAS  Google Scholar 

  70. Waring JP. Postfundoplication complications: prevention and management. Gastroenterol Clin North Am 1999; 28: 1007–19

    Article  PubMed  CAS  Google Scholar 

  71. Dall’Oglio L, Gatti C, Villa M, et al. A new and successful change in surgical treatment of gastroesophageal reflux in severely neurologically impaired children: Bianchi’s procedure. Eur J Pediatr Surg 2000; 10: 291–4

    Article  PubMed  Google Scholar 

  72. Gunasekaran TS, Hassall E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123: 148–54

    Article  PubMed  CAS  Google Scholar 

  73. Hassall E. Antireflux surgery in children: time for a harder look. Pediatrics 1998; 101: 467–8

    Article  PubMed  CAS  Google Scholar 

  74. Tsou VM, Young RM, Hart MH, et al. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991; 87: 148–51

    PubMed  CAS  Google Scholar 

  75. Woodard-Knight L, Fudge A, Teubner J, et al. Aluminium absorption and antacid therapy in infancy. J Paediatr Child Health 1992; 28: 257–9

    Article  PubMed  CAS  Google Scholar 

  76. Nurko S. Cisapride for the treatment of gastroestophageal reflux disease in children [letter]. J Pediatr Gastroenterol Nutr 1999; 29: 7

    Article  PubMed  CAS  Google Scholar 

  77. Cucchiara S, Staiano A, Boccieri A, et al. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut 1990; 31: 21–5

    Article  PubMed  CAS  Google Scholar 

  78. Cucchiara S, Staiano A, Capozzi C, et al. Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1987; 62: 454–7

    Article  PubMed  CAS  Google Scholar 

  79. Vandenplas Y, de Roy C, Sacre L. Cisapride decreases prolonged episodes of reflux in infants. J Pediatr Gastroenterol Nutr 1991; 12: 44–7

    Article  PubMed  CAS  Google Scholar 

  80. Scott RB, Ferreira C, Smith L, et al. Cisapride in pediatric gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1997; 25: 499–506

    Article  PubMed  CAS  Google Scholar 

  81. Van Eygen M, Van Ravensteyn H. Effect of cisapride on excessive regurgitation in infants. Clin Ther 1989; 11: 669–77

    PubMed  Google Scholar 

  82. Leung C, Lai W. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. Curr Ther Res 1984; 36: 911–5

    Google Scholar 

  83. Machida HM, Forbes DA, Gall DG, et al. Metoclopramide in gastroesophageal reflux of infancy. J Pediatr 1988; 112: 483–7

    Article  PubMed  CAS  Google Scholar 

  84. De Loore I, Van Ravensteyn H, Amerychx I. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation: a comparison with metoclopramide. Postgrad Med J 1979; 55: 40–2

    PubMed  Google Scholar 

  85. Bellissant E, Duhamel JF, Guillott M, et al. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Clin Pharmacol Ther 1997; 61: 377–84

    Article  PubMed  CAS  Google Scholar 

  86. Euler AR. Use of bethanechol for the treatment of gastroesophageal reflux. J Pediatr 1980; 96: 321–4

    Article  PubMed  CAS  Google Scholar 

  87. Levi P, Marmo F, Saluzzo C, et al. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta 1985; 40: 349–59

    PubMed  CAS  Google Scholar 

  88. Bines JE, Quinlan JE, Treves S, et al. Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1992; 14: 400–5

    Article  PubMed  CAS  Google Scholar 

  89. Carroccio A, Iacono G, Montalto G, et al. Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux — a double-blind randomized study versus placebo. Scand J Gastroenterol 1994; 29: 300–4

    Article  PubMed  CAS  Google Scholar 

  90. Putnam PE, Orenstein SR, Wessel HB, et al. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992; 121: 983–5

    Article  PubMed  CAS  Google Scholar 

  91. Merki HS, Wilder-Smith C, Walt R, et al. The cephalic and gastric phases of gastric acid secretion during H2 antagonist treatment. Gastroenterol 1991; 100: 599–606

    Google Scholar 

  92. Nwokolo CU, Smith JT, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine, or ranitidine. Aliment Pharmacol Ther 1990; 4Suppl. 1: 29–45

    PubMed  CAS  Google Scholar 

  93. Lachman L, Howden C. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57–61

    Article  PubMed  CAS  Google Scholar 

  94. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6(9 Suppl.): S491–505

    PubMed  CAS  Google Scholar 

  95. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related disease. J Am Pharm Assoc 2000; 40: 52–62

    CAS  Google Scholar 

  96. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22: 268–80

    Article  Google Scholar 

  97. Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol 2001; 13Suppl. 1: S5–11

    PubMed  Google Scholar 

  98. Blum RA, Shi H, Karol MD. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013–23

    Article  PubMed  CAS  Google Scholar 

  99. Jones RH, Baxter G. Lansoprazole 30mg daily versus ranitidine 150mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11: 541–6

    Article  PubMed  CAS  Google Scholar 

  100. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798–810

    Article  PubMed  CAS  Google Scholar 

  101. Huang J-Q, Hunt RH. Meta-analysis of comparative trials for healing erosive esophagitis (EE) with proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) [abstract]. Gastroenterology 1998; 114: A154

    Article  Google Scholar 

  102. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996; 91: 1758–65

    PubMed  CAS  Google Scholar 

  103. Sontag SJ, Kugut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997; 92: 429–37

    PubMed  CAS  Google Scholar 

  104. Robinson M, Campbell DR, Sontag S, et al. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy: lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995; 40: 590–7

    Article  PubMed  CAS  Google Scholar 

  105. Hassall E, Israel D, Shepherd R, et al., and the International Pediatric Omeprazole Study Group. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000; 137: 800–7

    Article  PubMed  CAS  Google Scholar 

  106. Abdullah B, Gupta SK, Fitzgerald JF, et al. Long-term management of moderate/severe peptic esophagitis in children/adolescents: H2 blocker vs proton pump inhibitor (PPI) [abstract]. Gastroenterology 1998; 114: A51

    Article  Google Scholar 

  107. Zimmermann AE, Walters JK, Katona BG, et al. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 2001; 23: 660–78

    Article  PubMed  CAS  Google Scholar 

  108. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000; 32: 660–6

    Article  PubMed  CAS  Google Scholar 

  109. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1397–402

    Article  PubMed  CAS  Google Scholar 

  110. Cucchiara S, Borrelli O, Gaudiello G, et al. Lansoprazole in children with severe gastroesophageal reflux disease: effect on gastric acidity, esophagitis and clinical outcome [abstract]. Gastroenterology 1999; 116: A142

    Google Scholar 

  111. Cucchiara S, Minella R, Campanozzi A, et al. Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Dig Dis Sci 1997; 42: 293–9

    Article  PubMed  CAS  Google Scholar 

  112. Nelis GF, Westerveld BD. Treatment of resistant reflux oesophagitis in children with omeprazole. Eur J Gastroenterol Hepatol 1990; 2: 215–7

    Google Scholar 

  113. Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolesc Med 1995; 149: 267–71

    Article  PubMed  CAS  Google Scholar 

  114. Martin PB, Imong SM, Krischer J, et al. The use of omeprazole for resistant oesophagitis in children. Eur J Pediatr Surg 1996; 6: 195–7

    Article  PubMed  CAS  Google Scholar 

  115. De Giacomo C, Bawa P, Franceschi M, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997; 24: 528–32

    Article  PubMed  Google Scholar 

  116. Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, et al. Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998; 152: 1113–8

    PubMed  CAS  Google Scholar 

  117. Strauss RS, Calenda KA, Dayal Y, et al. Histological esophagitis: clinical and histological response to omeprazole in children. Dig Dis Sci 1999; 44: 134–9

    Article  PubMed  CAS  Google Scholar 

  118. Alliet P, Raes M, Gillis P, et al. Treatment of refractory ulcerative oesophagitis with omeprazole [letter]. Arch Dis Child 1993; 68: 526

    Article  PubMed  CAS  Google Scholar 

  119. Gupta SK, Tolia V, Heyman MK, et al. Adolescent patients with gastroesophageal reflux disease: results from a randomized trial of lansoprazole [abstract]. Gastroenterology 2000; 118(9): A1242

    Article  Google Scholar 

  120. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of GERD in children [abstract]. Am J Gastroenterol 2000; 85(9): A122

    Google Scholar 

  121. Israel DM, Hassall E. Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998; 27: 568–79

    Article  PubMed  CAS  Google Scholar 

  122. Colletti RB, Hassall E, Heyman MB, et al. Use of proton pump inhibitors (PPIs) by pediatric gastroenterologists [abstract]. J Pediatr Gastroenterol Nutr 2001; 33: 414

    Google Scholar 

  123. Scott Levin & Associates. IMS America prescription audit. Newtown (PA): Scott Levin Audit, 2000

    Google Scholar 

  124. Mohiuddin MA, Pursnani KG, Katzka DA, et al. Effective gastric acid suppression after oral administration of enteric-coated omeprazole granules. Dig Dis Sci 1997; 42: 715–9

    Article  PubMed  CAS  Google Scholar 

  125. Zimmermann AE, Walters JK, Katona B, et al. Alternative methods of proton pump inhibitor administration. Consult Pharm 1997; 12: 990–8

    Google Scholar 

  126. Chun AHC, Erdman K, Zhang Y, et al. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. Clin Ther 2000; 22: 231–6

    Article  PubMed  CAS  Google Scholar 

  127. Chun AHC, Shi HH, Achari R, et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther 1996; 18: 833–42

    Article  PubMed  CAS  Google Scholar 

  128. Doan TT, Wang Q, Griffin JS, et al. Comparable pharmacokinetics and pharmacodynamics of lansoprazole oral capsule and suspension in healthy subjects. Am J Health Syst Pharm 2001; 58: 1512–9

    PubMed  CAS  Google Scholar 

  129. Sharma VK, Peyton B, Spears T, et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000; 14: 887–92

    Article  PubMed  CAS  Google Scholar 

  130. Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 56(23 Suppl.): S18–21

    PubMed  CAS  Google Scholar 

  131. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension, a liquid formulation of lansoprazole, effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol 1999; 94(7): 1813–7

    PubMed  CAS  Google Scholar 

  132. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes. Curr Opin Pediatr 1995; 7: 220–33

    Article  PubMed  CAS  Google Scholar 

  133. Jacqz-Aigrain E, Bellaich M, Faure C, et al. Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 1994; 47: 181–5

    PubMed  CAS  Google Scholar 

  134. Kato S, Ebina K, Fojii K, et al. Effect of omeprazole in the treatment of refractory acid related disease in childhood: endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996; 128: 415–21

    Article  PubMed  CAS  Google Scholar 

  135. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000; 95: 3101–6

    Article  PubMed  CAS  Google Scholar 

  136. Regardh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol Suppl 1986; 118: 99–104

    Article  PubMed  CAS  Google Scholar 

  137. Regardh CG, Gabrielsson M, Hoffman KJ, et al. Pharmacokinetics and metabolism of omeprazole in animals and man: an overview. Scand J Gastroenterol Suppl 1985; 108: 79–94

    Article  PubMed  CAS  Google Scholar 

  138. Cederberg C, Rohss K, Lundborg L, et al. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 28: 179–84

    Article  PubMed  CAS  Google Scholar 

  139. Cederberg C, Thomson AB, Mahachai V, et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103: 913–8

    PubMed  CAS  Google Scholar 

  140. Oosterhuis B, Jonkman JH, Andersson T, et al. No influence of single intravenous doses of omeprazole on theophylline kinetics. J Clin Pharmacol 1992; 32: 470–5

    PubMed  CAS  Google Scholar 

  141. Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002; 71(5): 359–67

    Article  PubMed  CAS  Google Scholar 

  142. Hendriks HG, van Kreel B, Forget PP. Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2001; 33: 260–5

    Article  PubMed  CAS  Google Scholar 

  143. Freston JW. Long-term acid control and proton pump inhibitors: interaction and safety issues in perspective. Am J Gastroenterol 1997; 92(4 Suppl.): 51–57S

    Google Scholar 

  144. Freston JW, Rose PA, Heller CA, et al. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf 1999; 20: 195–205

    Article  PubMed  CAS  Google Scholar 

  145. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661–9

    Article  PubMed  CAS  Google Scholar 

  146. Koop H, Naumann-Koch C, Arnold R. Effect of omeprazole on serum gastrin levels: influence of age and sex. Gastroenterology 1990; 28: 603–5

    CAS  Google Scholar 

  147. Freston JW, Borch K, Brand SJ, et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. Dig Dis Sci 1995; 40(2 Suppl.): 50–62S

    Article  Google Scholar 

  148. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990; 19: 141–53

    PubMed  CAS  Google Scholar 

  149. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002. In press

    Google Scholar 

  150. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404–30

    Article  PubMed  CAS  Google Scholar 

  151. Sachs G. The safety of omeprazole: true or false. Gastroenterology 1994; 106: 1400–1

    PubMed  CAS  Google Scholar 

  152. Lamberts R, Creutzfeldt W, Striber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 1993; 104: 1356–70

    PubMed  CAS  Google Scholar 

  153. Castell DO, Richter JE, Robinson M, et al., and the Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749–57

    PubMed  CAS  Google Scholar 

  154. Hassall E, Dimmick JE, Israel DM. Parietal cell hyperplasia in children receiving omeprazole [abstract]. Gastroenterology 1995; 108: A121

    Google Scholar 

  155. Israel DM, Dimmick JE, Hassall E. Gastric polyps in children on omeprazole [abstract]. Gastroenterology 1995; 108: A110

    Article  Google Scholar 

  156. Lee SW, Lieberman DA, Ippoliti AD, et al. Changes in the parietal cell mass after long term therapy with high dose omeprazole in Barrett’s esophagus (BE): a two year prospective study [abstract]. Gastroenterology 1996; 110: A173

    Google Scholar 

  157. Weinstein WM, Ang ST, Ippolitit AF, et al. Fundic gland polyps in patients on long term omeprazole therapy: a light and electron microscopic study of the gastric mucosa [abstract]. Gastroenterology 1994; 106: A210

    Google Scholar 

  158. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997–2000

    PubMed  CAS  Google Scholar 

  159. Bachmann KA, Sullivan TJ, Jauregui L, et al. Drug interactions of H2-receptor antagonists. Scand J Gastroenterol Suppl 1994; 206: 14–9

    Article  PubMed  CAS  Google Scholar 

  160. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacother 1996; 31(1): 9–28

    Article  CAS  Google Scholar 

  161. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8Suppl. 1: S21–5

    Article  PubMed  Google Scholar 

  162. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79–85

    Article  PubMed  CAS  Google Scholar 

  163. Andersson T, Andren K, Cederberg C, et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51–4

    Article  PubMed  CAS  Google Scholar 

  164. Zomorodi K, Houston JB. Diazepam-omeprazole inhibition interaction: an in vitroinvestigation using human liver microsomes. Br J Clin Pharmacol 1996; 42: 157–62

    Article  PubMed  CAS  Google Scholar 

  165. Sutfin T, Balmer K, Bostrom N, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176–84

    Article  PubMed  CAS  Google Scholar 

  166. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509–12

    Article  PubMed  CAS  Google Scholar 

  167. Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078–83

    Article  PubMed  Google Scholar 

  168. Cavanaugh JH, Karol MD. Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone. J Clin Pharmacol 1996; 36: 1064–71

    Article  PubMed  CAS  Google Scholar 

  169. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–41

    PubMed  CAS  Google Scholar 

  170. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543–5

    Article  PubMed  CAS  Google Scholar 

  171. Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415–6

    Article  PubMed  CAS  Google Scholar 

  172. Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 1990; 12: 329–33

    Article  PubMed  CAS  Google Scholar 

  173. Petersen K-U. Review article: omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995; 9: 1–9

    Article  PubMed  CAS  Google Scholar 

  174. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21(3): 195–212

    Article  PubMed  CAS  Google Scholar 

  175. Braeckman RA, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on a warfarin pharmacokinetics and anticoagulation effect in healthy subjects [abstract]. Pharm Res 1991; 8(10 Suppl.): S295

    Google Scholar 

  176. Cavanaugh JH, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on steady state warfarin metabolism [abstract]. Gastroenterology 1991; 100 (5 Pt 2): A40

    Google Scholar 

  177. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458–63

    Article  PubMed  CAS  Google Scholar 

  178. Karol MD, Mayersohn M, Eason CJ, et al. Evaluation of interaction potential between lansoprazole and clarithromycin (Biaxin®) in normal subjects [abstract]. 60th Annual Meeting of the American College of Gastroenterology; 1998 Oct 16–18; New York

  179. Cavanaugh JH, Schneck DW, Mukherji D, et al. Lack of effect of concomitant lansoprazole on single-dose propranolol pharmacokinetics and pharmacodynamics [abstract]. Gastroenterology 1994; 106(4): A4

    Google Scholar 

  180. Granneman GR, Karol MD, Locke CS, et al. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995; 17: 460–4

    Article  PubMed  CAS  Google Scholar 

  181. Pan WJ, Goldwater DR, Zhang Y, et al. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline. Aliment Pharmacol Ther 2000; 14: 345–52

    Article  PubMed  CAS  Google Scholar 

  182. Ko JW, Jang IJ, Shin JG, et al. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Clin Pharmacol Ther 1999; 65: 606–14

    Article  PubMed  CAS  Google Scholar 

  183. Karol MD, Locke CS, Cavanaugh JH. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin. J Clin Pharmacol 1999; 39: 1283–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr Gold is supported in part by a grant from National Institutes of Health (DK-53708) and serves as a consultant to Wyeth Research, Astra Zeneca, Prometheus Diagnostics, and TAP Pharmaceutical Products, Inc.

Dr Freston serves as a consultant for TAP Pharmaceutical Products, Inc., Takeda Pharmaceuticals North America, Astra Zeneca, and Pfizer.

Author information

Authors and Affiliations

  1. School of Medicine, Emory University, Atlanta, Georgia, USA

    Benjamin D. Gold

  2. University of Connecticut Health Center, Farmington, Connecticut, USA

    James W. Freston

Authors
  1. Benjamin D. Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. Freston
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gold, B.D., Freston, J.W. Gastroesophageal Reflux in Children. Pediatr-Drugs 4, 673–685 (2002). https://doi.org/10.2165/00128072-200204100-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204100-00004

Keywords

Search

Navigation